Regience, page-2

I copied and pasted the text to Google Translate and this is what was written:

The Company, March 3, 2016, signed a Cynata Therapeutics Ltd. (hereinafter referred to as "Cynata company") and the memorandum of understanding to consider a strategic business alliance for the production technology CymerusTM of iPS-derived MSC (mesenchymal stem cells).

The Company performs a basic agreement on business tie-up on Cynata Inc. and CymerusTM on December 2, 2015, we have advanced discussions on specific business alliances. This time, you will get the qualification of the use rights of CymerusTM in particular in Asia and Japan, make the study of the development and commercialization of regenerative medicine products using this technology. Based on this agreement, and if you decide to proceed with the development that we have to take advantage of the CymerusTM manufacturing technology, you can get an exclusive license of Asian countries, including Japan. …Continue